KLK3 and neoplasm: Our study investigated a cohort of hormone-sensitive prostate cancer (HSPC) patients at an early stage of disease recurrence after radical treatment (median PSA at PET scan 0.51 [IQR: 0.33–0.80] ng/mL), thus representing a potential low tumor burden population eligible for salvage treatment.